Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor
To the Editor: Linezolid is the first oxazolidinone antibiotic with labeling approved to treat methicillin-resistant Staphylococcus aureus (MRSA) infection. We report 3 cases of myelosuppression with red cell hypoplasia that occurred following therapy with linezolid. Although reversible thrombocytopenia has been reported in patients receiving more than 2 weeks of therapy,1 we found additional bone marrow changes that appear similar to those seen in reversible chloramphenicol toxicity.
Green SL, Maddox JC, Huttenbach ED. Linezolid and Reversible Myelosuppression. JAMA. 2001;285(10):1291. doi:10.1001/jama.285.10.1291
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.